NCT04064554CompletedNot Applicable
A Prospective, Randomized, Open-label, Single-centered Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Yonsei University
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Adverse Events
Study Overview
Brief Summary
The purpose of this study is to evaluate safety and immunogenicity of Bacillus Calmette-Guerin (BCG) delivery via Novel Micronjet600 device compared to those via conventional needle.
Detailed Description
This study is designed as prospective, randomized, open-label, single-centered. In this study, healthy adults who meet inclusion criteria will be randomized and receive a BCG vaccine either using a conventional needle or MicronJet600 device. After vaccination, adverse events and progress will be observed.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 35 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects who voluntarily consented, after listening enough explanation for this study and the characteristics of medical devices and BCG vaccines.
- •Adults from 19 to 35 years
- •Tuberculin Skin Test negative
- •QFT-GIT(QuantiFERON-TB Gold In-Tube) Test negative
- •BMI from 19 to 35
- •A person who is determined to be suitable for the clinical trial as a result of the screening test.
- •(Even if the physical, laboratory, imaging, or electrocardiogram results are out of the normal range, the subject may participate if he or she has provided a clear basis for participation at the discretion of the investigator.)
Exclusion Criteria
- •A person with a history of tuberculosis based on the medical history and chest radiograph, or who is suspected or confirmed to have a tuberculosis infection.
- •A person who has active fever except for mild acute upper respiratory infection or localized skin infection other than the site to be treated, or who has a fever of 38 °C or more within 1 week before application of the medical devices for the clinical trial.
- •A person who has not passed more than four weeks after the cure of virus infection (measles, mumps, chickenpox, and influenza).
- •A case that the subject has skin abrasions, open wounds, wounds, or scars on the site where the medical devices for the clinical trial.
- •A person who is unable to evaluate the local adverse effect because of tattoo, etc. on the site where the medical device for clinical trial is to be applied.
- •Patients with clinically significant arrhythmia difficult to participate in the clinical trial.
- •Patients with severe cardiac insufficiency (NYHA III and IV), a history of CABG(Coronary Artery Bypass Graft), and patients with cardiovascular diseases who are considered to be difficult to participate in the clinical trial.
- •A person with a known history of diabetes or a person whose diabetes was confirmed by a test.
- •Patients with hepatitis C or hepatitis B (in the case of hepatitis virus, healthy carriers may be participated at the discretion of the investigator) or positive for the serum test for human immunodeficiency virus (HIV).
- •Patients with severe immunosuppressive disease: congenital immunodeficiency such as severe combined immunodeficiency (SCID); leukemia; lymphoma, etc.
- •Patients with chronic renal insufficiency
- •A history of malignant tumors within 3 years excluding thyroid cancer (papillary, follicular, medullary types corresponding to Stage I or II), basal cell or squamous cell carcinoma on the skin, CIN(cervical intraepithelial neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma in other sites.
- •A case that a person has hypersensitivity or anamnesis for constitutivity constituting BCG.
- •Subjects who have not passed the predetermined period after receiving medication or treatment before the subjects participate in the clinical trial. (Refer to section 5.2.3.2)
- •Patients receiving concomitant medications (Refer to section 5.2.3.3)
- •A person who is unable to participate in the clinical trial period (about 6 months).
- •Patients scheduled for major surgery during the clinical trial.
- •A person who has a history of alcohol and other substance abuse for 6 months before screening.
- •Pregnant women or lactating women who are not willing to stop breastfeeding.
- •If the following are not applicable, (That is, you can only participate if):
- •Women(female?) in the menopause (non-therapy-induced amenorrhea for more than 12 months)
- •Infertility due to surgery (without ovaries and/or uterus)
- •If the female subject have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization
- •Female subjects who have agreed to abstinence during the clinical trial period
- •If the subject is assured of abstinence throughout the clinical trial period (only if abstinence is voluntarily selected by the subject and abstinence is consistent with the general lifestyle of the subject: e.g., Priest)
- •However, intermittent abstinence (e.g., ovulation, symptothermal method, or late ovulation) or external ejaculation is not a case of consent for abstinence.
- •In the case of a woman who is in childbearing years, a woman who decides to use an effective method of contraception during the clinical trial period:
- •Oral contraception
- •Patch for contraception
- •Intrauterine Contraceptive Device (IUD)
- •Implant for contraception
- •Injection for contraception (Time-released type)
- •Hormone device in the uterus
- •Tubal ligation and infertility surgery
- •Patient who has not passed 30 days since the date of signing the agreement of the previous clinical trial or who is currently participating in other clinical trial
- •Other diseases other than those listed above that the investigator deems inappropriate
Outcomes
Primary Outcomes
Adverse Events
Time Frame: during study period (Visit 3~Visit 6, 96 days)
Frequency and characteristics of adverse events after applying medical devices for clinical trials (aspect, materiality, results, etc.)
Secondary Outcomes
- Progress of normal reaction after BCG injection(Visit 3(day 1, after vaccination) ~ Visit 6 (from 2 or 3 day of the Visit 5(day 85±7)))
- Average of usability VAS for medical device user(Visit 3 (day 1))
- PPD test result (positive or negative) after application of medical device for clinical trial(Visit 6 (from 2 or 3 day of the Visit 5(day 85±7)))
- Fraction of subjects eligible for each grade in the injection fluid leakage assessment at the injection site(Visit 3 (day 1, immediately after vaccination))
- Delta log10 CFU(Visit 5(day 85±7))
- The diameter of the wheal(Visit 3 (day 1, after vaccination))
- Diameter of the scar after BCG injection(Visit 3(day 1, after vaccination) ~ Visit 6 (from 2 or 3 day of the Visit 5(day 85±7)))
- Spot Forming Unit (SFU) per PBMC(Peripheral Blood Mononuclear Cells)(Visit 1(day -28~2))
- Spot Forming Unit (SFU) per PBMC(Visit 5(day 85±7))
- Mycobacterial antigen specific T-cell(Visit 5(day 85±7))
- Diameter of induration (mm) or presence or absence of blister(Visit 6 (from 2 or 3 day of the Visit 5(day 85±7)))
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
To study the effect of BCG vaccine in Reducing the Incidence and severity of COVID-19 in the high-risk populatioCTRI/2020/07/026668Indian Council of Medical Research
Withdrawn
Phase 3
BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)Covid19NCT04534803Harvard Medical School (HMS and HSDM)
Completed
Phase 1
BCG Vaccination Delivered Intradermally, Orally and by Combined RoutesTuberculosisNCT00396370National Institute of Allergy and Infectious Diseases (NIAID)69
Completed
Phase 2
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate ADMild Cognitive ImpairmentMild DementiaModerate DementiaAlzheimer DiseaseNCT05004688Steven E Arnold, MD15
Terminated
Phase 2
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained InfectionTuberculosisNCT04152161Bill & Melinda Gates Medical Research Institute1,836